Xiaobing Lv

1.3k total citations
13 papers, 283 citations indexed

About

Xiaobing Lv is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Xiaobing Lv has authored 13 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Xiaobing Lv's work include Cancer-related molecular mechanisms research (3 papers), Cancer Mechanisms and Therapy (2 papers) and Biochemical and Molecular Research (2 papers). Xiaobing Lv is often cited by papers focused on Cancer-related molecular mechanisms research (3 papers), Cancer Mechanisms and Therapy (2 papers) and Biochemical and Molecular Research (2 papers). Xiaobing Lv collaborates with scholars based in China, United States and India. Xiaobing Lv's co-authors include Xin Hui, Zheng Zhao, Meng‐Die Cheng, Rui Zhang, Shuping Li, Jiawei Tian, Rong Li, Jing Shan, Yinfeng Zhang and Zhong Wang and has published in prestigious journals such as Nature Communications, Cancer Research and Diabetes.

In The Last Decade

Xiaobing Lv

12 papers receiving 281 citations

Peers

Xiaobing Lv

PRM

SURGE

EPIDE

Amit Ghosh India

Su-Jin Jeon South Korea

Zhenlei Wang China

Masami Komiya Japan

Qihua Gu China

Wangjia Cao China

Qianqian Chen China

Xian-Wei Li China

Junbao Liu China

Amit Ghosh India

Xiaobing Lv

192 ×1.0

171 ×1.1

49 ×0.7

PRM

18 ×0.6

SURGE

23 ×1.2

EPIDE

Citations per year, relative to Xiaobing Lv Xiaobing Lv (= 1×) peers Amit Ghosh

Countries citing papers authored by Xiaobing Lv

Since Specialization

Citations

This map shows the geographic impact of Xiaobing Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobing Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobing Lv more than expected).

Fields of papers citing papers by Xiaobing Lv

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaobing Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobing Lv. The network helps show where Xiaobing Lv may publish in the future.

Co-authorship network of co-authors of Xiaobing Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaobing Lv. A scholar is included among the top collaborators of Xiaobing Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaobing Lv. Xiaobing Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Lv, Xiaobing, et al.. (2025). Medication adherence and health empowerment in gout: a cross-sectional survey of patients. Rheumatology International. 45(8). 176–176. 1 indexed citations

Yang, Yanping, Xiaobing Lv, Kai Li, et al.. (2025). The correlation between serum MHR and NLR and the severity of coronary lesions in NSTE-ACS patients of different genders. Frontiers in Cardiovascular Medicine. 11. 1469730–1469730. 1 indexed citations

Lv, Xiaobing, et al.. (2024). Unlocking cardioprotection: iPSC exosomes deliver Nec-1 to target PARP1/AIFM1 axis, alleviating HF oxidative stress and mitochondrial dysfunction. Journal of Translational Medicine. 22(1). 681–681. 6 indexed citations

Tian, Jiawei, Xiaobing Lv, Rong Li, et al.. (2024). Crosstalk between ubiquitin ligases and ncRNAs drives cardiovascular disease progression. Frontiers in Immunology. 15. 1335519–1335519. 3 indexed citations

Chen, Chen, Charles Huang, Min Xu, et al.. (2023). Abstract 5982: A potent and selective CDK8 inhibitor ABM-3249 with excellent efficacies in multiple in vivo cancer models. Cancer Research. 83(7_Supplement). 5982–5982. 1 indexed citations

Chen, Chen, Charles Y. Huang, Min Xu, et al.. (2023). Abstract 476: ABM-1310 has significant improved BBB-penetration and intracranial tumor growth inhibition compared to FDA approved BRAF inhibitors. Cancer Research. 83(7_Supplement). 476–476.

Zhang, Yinfeng, Rui Zhang, Jiawei Tian, et al.. (2022). Ferroptosis in Cancer Progression: Role of Noncoding RNAs. International Journal of Biological Sciences. 18(5). 1829–1843. 106 indexed citations

Zhu, Wenxiu, Rui Zhang, Song Liu, et al.. (2021). The effect of nanoparticles of cobalt–chromium on human aortic endothelial cells in vitro. Journal of Applied Toxicology. 41(12). 1966–1979. 7 indexed citations

Lv, Xiaobing, et al.. (2020). Critical functions of microRNA‐30a‐5p‐E2F3 in cardiomyocyte apoptosis induced by hypoxia/reoxygenation. The Kaohsiung Journal of Medical Sciences. 37(2). 92–100. 8 indexed citations

10.

Zhang, Min, et al.. (2020). Circular RNA (circRNA) CDYL Induces Myocardial Regeneration by ceRNA After Myocardial Infarction. Medical Science Monitor. 26. e923188–e923188. 48 indexed citations

11.

Padyana, Anil K., Stefan Größ, Lei Jin, et al.. (2019). Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase. Nature Communications. 10(1). 99 indexed citations

12.

Chen, Li, Yongqiang Shan, Xiaowei Jin, & Xiaobing Lv. (2019). 1151-P: Dorzagliatin Differentiates from Early Generation of Glucokinase Activators: An Enzyme Kinetics Study. Diabetes. 68(Supplement_1). 2 indexed citations

13.

Lv, Xiaobing, et al.. (2008). [Energy charge changing by pathway manipulation of adenosine triphosphate metabolism in Escherichia coli].. PubMed. 48(1). 26–32. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact